+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Coagulation Factor XI - Pipeline Review, H1 2020

  • ID: 5027052
  • Drug Pipelines
  • April 2020
  • Region: Global
  • 69 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Anthos Therapeutics Inc
  • Aronora Inc
  • Bayer AG
  • Bristol-Myers Squibb Co
  • Cambryn Biologics LLC
  • Ionis Pharmaceuticals Inc
  • MORE
Coagulation Factor XI - Pipeline Review, H1 2020

Summary

According to the recently published report 'Coagulation Factor XI - Pipeline Review, H1 2020'; Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) pipeline Target constitutes close to 22 molecules. Out of which approximately 21 molecules are developed by companies and remaining by the universities/institutes.

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Factor XI or plasma thromboplastin antecedent is the zymogen form of factor Xia. Factor XI triggers the middle phase of the intrinsic pathway of blood coagulation by activating factor IX. Inhibitors of factor XIa include protein Z-dependent protease inhibitor.

The report 'Coagulation Factor XI - Pipeline Review, H1 2020' outlays comprehensive information on the Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I and Preclinical stages are 6, 9 and 6 respectively.

Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. The report covers products from therapy areas Cardiovascular, Hematological Disorders and Infectious Disease which include indications Thrombosis, Arterial Thrombosis, Venous Thromboembolism, Bleeding And Clotting Disorders, Venous (Vein) Thrombosis, Acute Ischemic Stroke, Hemophilia C (Factor XI Deficiency), Sepsis, Stroke, Atrial Fibrillation, Cerebral Infarction (Brain Infarction), Hemorrhagic Fever, Ischemic Stroke and Myocardial Infarction.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27)
  • The report reviews Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics
Reasons to Buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Anthos Therapeutics Inc
  • Aronora Inc
  • Bayer AG
  • Bristol-Myers Squibb Co
  • Cambryn Biologics LLC
  • Ionis Pharmaceuticals Inc
  • MORE
  • Introduction
  • Report Coverage
  • Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Overview
  • Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Companies Involved in Therapeutics Development
  • Anthos Therapeutics Inc
  • Aronora Inc
  • Bayer AG
  • Bio Products Laboratory Ltd
  • Bristol-Myers Squibb Co
  • Cambryn Biologics LLC
  • eXithera Pharmaceuticals Inc
  • Ionis Pharmaceuticals Inc
  • Jiangsu Hengrui Medicine Co Ltd
  • Mochida Pharmaceutical Co Ltd
  • Ono Pharmaceutical Co Ltd
  • Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Drug Profiles
  • 7300 Series - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AB-012 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AB-022 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • abelacimab [INN] - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BAY-1831865 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BAY-2433334 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BMS-262084 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BMS-654457 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BMS-962212 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • coagulation factor XI (human) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • coagulation factor XI (human) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • coagulation factor XI (human) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • EP-7041 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • IONIS-FXILRx - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • IONIS-FXIRx - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • milvexian - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MR-1007 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ONO-7269 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ONO-7684 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • osocimab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SHR-2285 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit Factor XI for Bleeding And Clotting Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit Factor XIa for Arterial Thrombosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Dormant Products
  • Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Product Development Milestones
  • Featured News & Press Releases
  • Oct 28, 2019: Ionis Pharmaceuticals presents on its drug candidate IONIS-FXI-LRx at DIA/FDA Oligonucleotide Conference
  • Oct 09, 2019: Ionis' Factor XI anti-thrombotic medicine advances with Bayer following positive clinical results
  • Nov 13, 2017: eXIthera Presents Clinical Data on Novel Small Molecule FXIa Inhibitor EP-7041 at American Heart Association
  • Jul 03, 2017: Bayer To Present Data on BAY 1213790 at ISTH 2017
  • Nov 01, 2016: Ionis Pharmaceuticals Reports Positive Phase 2 Data for IONIS-FXI Rx in Patients with End-Stage Renal Disease on Hemodialysis
  • Jul 04, 2016: MorphoSys Receives Clinical Milestone for Start of Phase 1 Trial in Prevention of Thrombosis with Novel Antibody
  • Oct 30, 2015: Isis Pharmaceuticals Initiates Phase 2 Study of ISIS-FXI Rx in Patients with End-Stage Renal Disease on Hemodialysis
  • Feb 24, 2015: Bayer HealthCare and Aronora Establish Partnership for the Pre-Clinical Manufacturing of AB-022
  • Dec 07, 2014: Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx for the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery
  • Nov 18, 2014: Isis Pharmaceuticals To Host Webcast To Discuss ISIS-FXI Rx Data Presented At The ASH Annual Meeting
  • May 22, 2014: Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx in the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery
  • May 22, 2014: Cambryn Biologics Receives From FDA Orphan Drug Designation For Human Factor XI
  • Apr 19, 2013: CML HealthCare's Subsidiary Hemostasis Reference Labs Receives Contract Extension From Isis Pharma
  • Oct 29, 2012: Isis Pharma Initiates Phase II Study Of ISIS-FXIRX In Patients Undergoing Knee Replacement Surgery
  • Dec 12, 2011: Isis Reports Positive Phase I Data Demonstrating ISIS-FXIRx Reduces Factor XI Activity Without Bleeding
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Information
  • Disclaimer
List of Tables
  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Indication, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Investigation by Universities/Institutes, H1 2020
  • Products under Investigation by Universities/Institutes, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Pipeline by Anthos Therapeutics Inc, H1 2020
  • Pipeline by Aronora Inc, H1 2020
  • Pipeline by Bayer AG, H1 2020
  • Pipeline by Bio Products Laboratory Ltd, H1 2020
  • Pipeline by Bristol-Myers Squibb Co, H1 2020
  • Pipeline by Cambryn Biologics LLC, H1 2020
  • Pipeline by eXithera Pharmaceuticals Inc, H1 2020
  • Pipeline by Ionis Pharmaceuticals Inc, H1 2020
  • Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2020
  • Pipeline by Mochida Pharmaceutical Co Ltd, H1 2020
  • Pipeline by Ono Pharmaceutical Co Ltd, H1 2020
  • Dormant Projects, H1 2020
List of Figures
  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Top 10 Indications, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Anthos Therapeutics Inc
  • Aronora Inc
  • Bayer AG
  • Bio Products Laboratory Ltd
  • Bristol-Myers Squibb Co
  • Cambryn Biologics LLC
  • eXithera Pharmaceuticals Inc
  • Ionis Pharmaceuticals Inc
  • Jiangsu Hengrui Medicine Co Ltd
  • Mochida Pharmaceutical Co Ltd
  • Ono Pharmaceutical Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll